Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)
Marker Therapeutics (MRKR) posted quarterly Operating Leases of $6.8 million for Q1 2023, down 41.68% year-over-year from $11.7 million in Q1 2022, and down 3.06% quarter-over-quarter from $7.0 million in Q4 2022.
Marker Therapeutics (MRKR) Operating Leases (2019 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Operating Leases for 5 consecutive years, with $6.8 million the latest figure, recorded in Q1 2023.
- In Q1 2023, Operating Leases fell 41.68% year-over-year to $6.8 million; the TTM figure through Mar 2023 stood at $6.8 million (down 41.68% YoY), while the FY2022 annual figure was $7.0 million, down 37.42% from the prior year.
- Operating Leases declined to $6.8 million in Q1 2023 per MRKR's latest filing, from $7.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $12.2 million in Q3 2020 and bottomed at $226111.0 in Q1 2020.
- Historically, Operating Leases has averaged $7.4 million across 5 years, with a median of $9.0 million in 2020.
- Annual changes were most pronounced in 2020 — Operating Leases slumped 66.25% — and 2021, when it jumped 5292.48%.
- Marker Therapeutics' Operating Leases stood at $280247.0 in 2019, then jumped by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then sank by 37.42% to $7.0 million in 2022, then slipped by 3.06% to $6.8 million in 2023.
- Business Quant data shows MRKR's Operating Leases at $6.8 million in Q1 2023, $7.0 million in Q4 2022, and $7.2 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 6.82 Mn |
| Dec 31, 2022 | 7.04 Mn |
| Sep 30, 2022 | 7.23 Mn |
| Jun 30, 2022 | 10.82 Mn |
| Mar 31, 2022 | 11.70 Mn |
| Dec 31, 2021 | 11.25 Mn |
| Sep 30, 2021 | 11.43 Mn |
| Jun 30, 2021 | 11.57 Mn |
| Mar 31, 2021 | 12.19 Mn |
| Dec 31, 2020 | 11.87 Mn |
| Sep 30, 2020 | 12.20 Mn |
| Jun 30, 2020 | 9.03 Mn |
| Mar 31, 2020 | 226,111.00 |
| Dec 31, 2019 | 280,247.00 |
| Sep 30, 2019 | 533,000.00 |
| Jun 30, 2019 | 385,169.00 |
| Mar 31, 2019 | 670,000.00 |